Based on the efficacy of these treatments, it has been anticipated that they will improve long-term survival of patients with epidermal growth factor receptor (EGFR) mutation-positive NSCLC after the administration of EGFR tyrosine kinase inhibitors (TKIs). Here, EGFR is linked to non-small cell lung carcinoma.